JP Morgan maintains Merck & Co at Overweight, raises price target to $175 from $165

What happened

JP Morgan kept its Overweight rating on Merck & Co and raised its price target to $175 from $165, an increase of 6.1%. The new target implies 17.0% upside from Merck’s Oct. 30 closing price of $149.52.

Confirmed

Global impact / market context

The higher target signals that JP Morgan sees more potential for Merck shares than before, but it is an analyst estimate, not a company commitment or a guaranteed return. It could influence investor expectations and positioning, while the rating remains unchanged.

Analyst inference

Recent analyst targets were spread from $140 to $180 across five notes published over 30 days. JP Morgan’s $175 target sits near the upper end of that range, showing that analysts differ meaningfully in their views of Merck’s potential share value.

Confirmed

What to watch

1. Compare later analyst targets with JP Morgan’s $175 figure and the reported $140–$180 range to see whether views are converging or diverging. Analyst inference
2. Watch for changes to JP Morgan’s Overweight rating or target; the article reports the rating was maintained while the target rose from $165. Analyst inference
3. Track Merck’s share price against the Oct. 30 close of $149.52; the stated 17.0% upside is calculated from that reference price. Confirmed

Evidence

• Original source link unavailable